Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by KBC Group NV

KBC Group NV raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 236,318 shares of the specialty pharmaceutical company’s stock after buying an additional 8,014 shares during the period. KBC Group NV’s holdings in Jazz Pharmaceuticals were worth $29,103,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Blue Trust Inc. grew its stake in Jazz Pharmaceuticals by 83.7% during the 4th quarter. Blue Trust Inc. now owns 1,868 shares of the specialty pharmaceutical company’s stock worth $230,000 after buying an additional 851 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Jazz Pharmaceuticals by 2.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock worth $868,000 after acquiring an additional 155 shares during the last quarter. Lmcg Investments LLC acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $5,599,000. MassMutual Private Wealth & Trust FSB raised its position in shares of Jazz Pharmaceuticals by 26,389.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 17,748 shares of the specialty pharmaceutical company’s stock valued at $2,186,000 after purchasing an additional 17,681 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In other news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,253 shares of company stock worth $1,001,434 over the last three months. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $123.53 on Wednesday. The firm has a market cap of $7.47 billion, a PE ratio of 17.40, a P/E/G ratio of 0.87 and a beta of 0.56. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a 50-day moving average price of $122.64 and a 200 day moving average price of $115.70.

Analyst Ratings Changes

A number of brokerages have issued reports on JAZZ. Needham & Company LLC restated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. TD Cowen cut their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.